Corbus Pharmaceuticals Files 8-K
Ticker: CRBP · Form: 8-K · Filed: Oct 30, 2025 · CIK: 1595097
Sentiment: neutral
Topics: 8-k, regulatory-filing
Related Tickers: CRBP
TL;DR
CRBP filed an 8-K on 10/30/25 for 'Other Events' - details TBD.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on October 30, 2025, to report on other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This 8-K filing indicates that Corbus Pharmaceuticals Holdings, Inc. has reported an event, but the lack of specific details requires further investigation to understand its implications.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant corporate changes.
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- October 30, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Norwood, Massachusetts (location) — Principal Executive Offices
FAQ
What specific event is Corbus Pharmaceuticals Holdings, Inc. reporting on in this 8-K filing?
The filing is categorized under 'Other Events' and does not specify the nature of the event within the provided text.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is October 30, 2025.
What is the principal executive office address for Corbus Pharmaceuticals Holdings, Inc.?
The principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts 02062.
What is the IRS Employer Identification Number (EIN) for Corbus Pharmaceuticals Holdings, Inc.?
The IRS Employer Identification Number is 46-4348039.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2025-10-30 16:34:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
- $104.0 million — lents, and investments of approximately $104.0 million as of September 30, 2025, which include
- $27.0 million — s of September 30, 2025, which includes $27.0 million in cash and cash equivalents. The actua
Filing Documents
- crbp-20251030.htm (8-K) — 45KB
- 0001193125-25-258692.txt ( ) — 156KB
- crbp-20251030.xsd (EX-101.SCH) — 31KB
- crbp-20251030_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. Financial Update and Preliminary Financial Information for the Quarter Ended September 30, 2025 Corbus Pharmaceuticals Holdings, Inc. (the "Company") has not finalized its financial statements as of and for the quarter ended September 30, 2025. Based on its current estimates, the Company expects to report that it had cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025, which includes $27.0 million in cash and cash equivalents. The actual amounts that the Company will report will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its financial results for the quarter ended September 30, 2025 are finalized and filed with the U.S. Securities and Exchange Commission. The preliminary financial data included herein has been prepared by, and is the responsibility of, management. The Company's independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data and, accordingly, does not express an opinion or any other form of assurance with respect thereto. This estimate should not be viewed as a substitute for financial statements prepared in accordance with accounting principles generally accepted in the United States. It does not reflect any updates following September 30, 2025, including any sales made under the Open Market Sale Agreement, dated August 6, 2020, by and between the Company and Jefferies LLC, as amended, following such date, or consider any events or circumstances after the date that it was prepared, and is not necessarily indicative of the results to be achieved in any future period. Accordingly, you should not place undue reliance on this preliminary estimate. The Company assumes no duty to update this preliminary estimate except as required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: October 30, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer